TEST:

Stockholm3

"A landmark study with nine-year follow-up, recently published in European Urology, demonstrates that Stockholm3 can detect aggressive and potentially lethal prostate cancers among men with PSA levels in the 1.5 - 3 ng/ml range. The study showed that these men, who had a positive Stockholm3, were nine times more likely (hazard ratio of 8.8) to have a high-risk biochemical recurrence after treatment than men with PSA 3 ng/ml or higher, and a negative Stockholm3. Approximately 20-30% of men aged 50-75 years have a PSA between 1.5 – 3 ng/ml."

Some men with PSA <3 ng/ml harbor aggressive PCa with a substantial risk of recurrence after upfront curative treatment. Risk predictive blood tests, such as Stockholm3, used at lower PSA thresholds, can identify these men, while few clinically important cancers are missed when biopsy is deferred with PSA ≥3 ng/ml but low Stockholm3 scores.

P=N/A, N=7500, Active, not recruiting, Karolinska Institutet

For most of our 26 patients on AS with a Stockholm3 score of <15, confirmatory biopsy revealed GG 1 and benign histology. A confirmatory biopsy should be recommended for all patients with PI-RADS ≥4 lesions irrespective of their Stockholm3 score, but could be avoided in cases with negative MRI findings and a Stockholm3 score of <15.

We observed a substantial testing rate of 33% between STHLM3-MRI screening rounds, but few PCa cases were detected among men with lower risk. Most cancers were diagnosed in the elevated-risk group. A reduction in opportunistic testing in lower-risk groups will be crucial for optimising the benefits of future screening programmes.

These findings should be externally validated and evaluated for cost-effectiveness. STHLM3-MRI clinical trial is funded by the Swedish Cancer Society (Cancerfonden), the Swedish Research Council (Vetenskapsrådet), the Swedish Research Council for Health Working Life and Welfare (FORTE), the Strategic Research Programme on Cancer (StratCan), Hagstrandska Minnesfonden, Region Stockholm, Svenska Druidorden, Åke Wibergs Stiftelse, the Swedish e-Science Research Centre, the Karolinska Institutet, and Prostatacancerförbundet.

Compared with free/total PSA, Stockholm3 could reduce unnecessary biopsies by 44% while maintaining a 0.95 sensitivity. Stockholm3 outperforms other commonly used biomarkers and risk calculators for detecting GG ≥ 2 cancer in a diverse population.

P=N/A, N=199, Completed, Karolinska Institutet | Recruiting --> Completed | N=400 --> 199 | Trial completion date: Dec 2024 --> Jul 2024

"A new article, published in European Urology Oncology highlights the effectiveness of Stockholm3 in improving repeat screening for prostate cancer. The clinical study demonstrated that using Stockholm3 instead of traditional prostate-specific antigen (PSA) testing increased detection of clinically significant cancers by 31%, without increasing the need for magnetic resonance imaging."

Stockholm3 outperforms other commonly used biomarkers and risk calculators for detecting clinically significant prostate cancer in an ethnically and racially diverse population.

Stockholm3 outperforms other commonly used biomarkers and risk calculators for detecting clinically significant prostate cancer in an ethnically and racially diverse population.